The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer

Oncotarget

Volumn 7, Issue 17, 2016, Pages 24810-24823

  Mao, Yuan ^a   Wang, Xiaoying ^b,c   Zheng, Feng ^b   Wang, Changjun ^b   Tang, Qi ^c   Tang, Xiaojun ^c   Xu, Ning ^c   Zhang, Huiling ^d   Zhang, Dawei ^e   Xiong, Lin ^e   Liang, Jie ^f   Zhu, Jin ^b,c  

^a Jiangsu Province Geriatric Hospital   (China)

^b Huadong Medical Institute of Biotechniques   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University   (China)

Author keywords

ADC; DOX; Fab; Pancreatic carcinoma; Trop2

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; TROP2 FAB ANTIBODY; TROPHOBLASTIC CELL SURFACE ANTIGEN 2; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CELL ADHESION MOLECULE; TROP2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ADULT; AGE DISTRIBUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; HUMAN; IC50; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN EXPRESSION; SEX DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; MORTALITY; NUDE MOUSE; PANCREAS TUMOR; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MICE; MICE, NUDE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84966638746     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8529     Document Type: Article

References (56)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61:212-236.
2. Wang X, Wang L, Mo Q, Dong Y, Wang G, Ji A. Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. Int J Clin Exp Pathol. 2015; 8:5702-5708.
3. Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, Liu L. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014; 4:5911.
4. McGlynn LM, McCluney S, Jamieson NB, Thomson J, MacDonald AI, Oien K, Dickson EJ, Carter CR, McKay CJ, Shiels PG. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. PLoS One. 2015; 10:e0131344.
5. Wang Q, Ni Q, Wang X, Zhu H, Wang Z, Huang J. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med Oncol. 2015; 32:372.
6. Guillaumond F, Iovanna JL, Vasseur S. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways. Arch Biochem Biophys. 2014; 545:69-73.
7. Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, Alberti S. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer. 1995; 62:610-618.
8. Chen R, Lu M, Wang J, Zhang D, Lin H, Zhu H, Zhang W, Xiong L, Ma J, Mao Y, Zhu J, Xu J. Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Arch. 2013; 463:713-719.
9. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer. 1998; 76:671-676.
10. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, Li H, Wang CJ, Wang ZC, Feng ZQ, Zhu J. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol. 2013; 94:73-78.
11. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009; 24:875-884.
12. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Muller HM, Margreiter R, Ofner D, Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009; 62:152-158.
13. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009; 1796:309-314.
14. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008; 7:280-285.
15. Wu H, Xu H, Zhang S, Wang X, Zhu H, Zhang H, Zhu J, Huang J. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck. 2013; 35:1373-1378.
16. Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, Zhao P, Zhu J, Mao Y, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014; 134:1239-1249.
17. Liu Z, Feng Z, Zhu X, Xu W, Zhu J, Zhang X, Fan Z, Ji G. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL. Immunol Lett. 2013; 149:30-40.
18. Ayla S, Seckin I, Tanriverdi G, Cengiz M, Eser M, Soner BC, Oktem G. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol. 2011; 2011:390238.
19. Fulop Z, Gref R, Loftsson T. A permeation method for detection of self-aggregation of doxorubicin in aqueous environment. Int J Pharm. 2013; 454:559-561.
20. Matsudaira H, Asakura T, Aoki K, Searashi Y, Matsuura T, Nakajima H, Tajiri H, Ohkawa K. Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSHDXR conjugate on CD147 highly expressed carcinoma cells. Int J Oncol. 2010; 36:77-83.
21. Etrych T, Mrkvan T, Rihova B, Ulbrich K. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J Control Release. 2007; 122:31-38.
22. Chen X, Ding G, Gao Q, Sun J, Zhang Q, Du L, Qiu Z, Wang C, Zheng F, Sun B, Ni J, Feng Z, Zhu J. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One. 2013; 8:e63093.
23. Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther. 2014; 7:2227-2236.
24. Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam MH, Hu W, Charati MB, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015; 14:952-963.
25. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Antibodydrug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014; 1321:41-54.
26. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Sitespecific antibody drug conjugates for cancer therapy. MAbs. 2014; 6:34-45.
27. Ramsland PA, Hutchinson AT, Carter PJ. Therapeutic antibodies: Discovery, design and deployment. Mol Immunol. 2015.
28. Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013; 73:3155-3167.
29. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M, Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008; 21:186-191.
30. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010; 46:944-953.
31. van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lutje S, McBride WJ, Oyen WJ, Boerman OC. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2xAnti-HSG Bispecific Antibody and a (177) Lu-Labeled Peptide. Cancer Biother Radiopharm. 2014; 29:323-329.
32. Liu T, Tian J, Chen Z, Liang Y, Liu J, Liu S, Li H, Zhan J, Yang X. Anti-TROP2 conjugated hollow gold nanospheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells. Nanotechnology. 2014; 25:345103.
33. Stein R, Basu A, Goldenberg DM, Lloyd KO, Mattes MJ. Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer Suppl. 1994; 8:98-102.
34. Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res. 1995; 55:5857s-5863s.
35. Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 2004; 84:173-182.
36. Iyer U, Kadambi VJ. Antibody drug conjugates-Trojan horses in the war on cancer. J Pharmacol Toxicol Methods. 2011; 64:207-212.
37. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010; 14:529-537.
38. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011; 17:3157-3169.
39. Friedrich L, Stangl S, Hahne H, Kuster B, Kohler P, Multhoff G, Skerra A. Bacterial production and functional characterization of the Fab fragment of the murine IgG1/ lambda monoclonal antibody cmHsp70.1, a reagent for tumour diagnostics. Protein Eng Des Sel. 2010; 23:161-168.
40. Zhang X, Xiao GG, Gao Y. Characterization of human colorectal cancer MDR1/P-gp Fab antibody. Scientific World Journal. 2013; 2013:716289.
41. Sharkey RM, van Rij CM, Karacay H, Rossi EA, Frielink C, Regino C, Cardillo TM, McBride WJ, Chang CH, Boerman OC, Goldenberg DM. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers. J Nucl Med. 2012; 53:1625-1632.
42. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006; 12:3057-3063.
43. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008; 99:1290-1295.
44. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002; 62:819-826.
45. Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu H, Xu N, Zhang D, Xiong L, Mao Y, Zhu J. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer. Exp Mol Pathol. 2014; 97:579-584.
46. Gu X, Fu M, Ge Z, Zhan F, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, Li J, Qiu L, Mao Y, et al. High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma. Sci Rep. 2014; 4:6625.
47. Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, Li QD, Ma J, Cao Q, Chen RJ, Zhu J, Feng ZQ. Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2012; 31:101.
48. Han L, Jiang B, Wu H, Zhang S, Lu X. Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7:6734-6742.
49. Xian H, Zhang H, Zhu H, Wang X, Tang X, Mao Y, Zhu J. High APRIL expression correlates with unfavourable survival of gastrointestinal stromal tumour. Pathology. 2014; 46:617-622.
50. Zhu H, Lu J, Wang X, Zhang H, Tang X, Zhu J, Mao Y. Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor. Med Oncol. 2013; 30:631.
51. Ma J, Wang J, Fan W, Pu X, Zhang D, Fan C, Xiong L, Zhu H, Xu N, Chen R, Liu S. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7:246-254.
52. Ni S, Xu L, Huang J, Feng J, Zhu H, Wang G, Wang X. Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2013; 6:2887-2895.
53. Mao Y, Zhang DW, Zhu H, Lin H, Xiong L, Cao Q, Liu Y, Li QD, Xu JR, Xu LF, Chen RJ. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol. 2012; 7:178.
54. Shi C, Yang X, Ni Y, Hou N, Xu L, Zhan F, Zhu H, Xiong L, Chen P. High Rab27A expression indicates favorable prognosis in CRC. Diagn Pathol. 2015; 10:68.
55. Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, Liang J, Feng Z. A human Fabbased immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2012; 11:594-603.
56. Lin H, Mao Y, Zhang DW, Li H, Qiu JR, Zhu J, Chen RJ. Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin. Anticancer Agents Med Chem. 2013; 13:1259-1266.